Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...
Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system-a group of proteins that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results